OpGen Pivots to FinTech, Launches Capital Markets Advisory Arm

TL;DR

**OpGen's complete pivot to FinTech is a high-risk, high-reward gamble; stay away until CapForce shows concrete revenue and client traction.**

AI Summary

OPGEN INC (OPGN) underwent a significant strategic pivot in 2024, shifting from a precision medicine company to a financial services and technology firm. This transformation followed the insolvency proceedings of its subsidiaries, Curetis and Ares Genetics, in November 2023, leading to their deconsolidation and asset sales to Camtech Pte Ltd. and bioMerieux S.A. respectively in April 2024. The company secured $3.0 million in gross proceeds from the sale of Series E Convertible Preferred Stock to David E. Lazar in March 2024, which was subsequently acquired by AEI Capital Ltd. for $2.45 million in August 2024. AEI Capital Ltd. then converted all 3,000,000 Series E Preferred Stock into 7,200,000 shares of common stock. Under AEI Capital Ltd.'s direction, OpGen established CapForce International Holdings Ltd., a wholly-owned subsidiary, to offer capital market listing sponsorship and consultancy services, targeting mid-sized growth-stage private companies with market capitalizations between $1 billion and $10 billion. CapForce is also developing a next-generation global digital investment banking platform for cross-border securities trading, computational model-enabled advisory, and FinTech-enabled cap table management. The company also effected 1-for-20 and 1-for-10 reverse stock splits on January 5, 2023, and May 20, 2024, respectively.

Why It Matters

This dramatic strategic pivot by OpGen, now controlled by AEI Capital Ltd., fundamentally alters its investment thesis. Investors are no longer betting on molecular diagnostics but on the nascent success of a financial services and technology platform, CapForce, in a highly competitive market. Employees from the previous precision medicine operations have likely been impacted by the headcount reductions and scaling down of U.S. operations. Customers of the former OpGen and its subsidiaries will need to seek alternative providers for molecular microbiology solutions. The broader market will observe if a company can successfully execute such a drastic industry shift, especially with a new leadership and a focus on Asian issuers for listing services, potentially impacting the competitive landscape for traditional investment banks and FinTech platforms.

Risk Assessment

Risk Level: high — The company has undergone a complete business model transformation, shifting from precision medicine to financial services and technology. This involves entering new, highly competitive markets with unproven products and services through its new subsidiary, CapForce. The filing indicates a market value of voting common stock held by non-affiliates of only $3.3 million as of June 30, 2024, and its common stock is currently quoted on the OTC Expert Market, indicating significant liquidity and market development risks.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Wait for CapForce to demonstrate tangible client acquisition, revenue generation, and regulatory compliance in its new financial services ventures before considering any position. The current business model is entirely unproven.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $3.0 million — Gross proceeds from Series E Preferred Stock sale (Secured in March 2024 from David E. Lazar)
• $2.45 million — Payment from AEI Capital Ltd. (For remaining Series E Preferred Stock in August 2024)
• 7,200,000 shares — Common stock converted from Series E Preferred Stock (All Series E Preferred Stock converted in August 2024)
• $3.3 million — Aggregate market value of voting common stock held by non-affiliates (As of June 30, 2024, indicating small market capitalization)
• $2.58 per share — Last reported sale price of common stock (On June 30, 2024)
• 10,071,293 shares — Common stock outstanding (As of August 20, 2025)
• 1-for-20 — Reverse stock split ratio (Effected on January 5, 2023)
• 1-for-10 — Reverse stock split ratio (Effected on May 20, 2024)
• $1 billion to $10 billion — Target market capitalization for CapForce clients (For listing sponsorship services)

Key Players & Entities

• OPGEN INC (company) — registrant
• Curetis N.V. (company) — acquired in April 2020 business combination
• Curetis GmbH (company) — subsidiary that filed for insolvency in November 2023
• Ares Genetics GmbH (company) — subsidiary that filed for insolvency in November 2023
• Camtech Pte Ltd. (company) — purchased all of Curetis' assets in April 2024
• bioMerieux S.A. (company) — purchased all of Ares Genetics' assets in April 2024
• David E. Lazar (person) — former CEO, Chairman, and Director; sold Series E Preferred Stock to AEI Capital Ltd.
• AEI Capital Ltd. (company) — controlling shareholder; acquired Series E Preferred Stock and directed strategic pivot
• CapForce International Holdings Ltd. (company) — wholly-owned subsidiary for new financial services and technology business
• U.S. Securities and Exchange Commission (regulator) — filing oversight

FAQ

Risk Factors

• Insolvency of Subsidiaries [high — financial]: In November 2023, subsidiaries Curetis and Ares Genetics filed for insolvency proceedings in Germany and Austria, respectively. This led to their deconsolidation from OpGen's financial statements and the subsequent sale of their assets in April 2024. The loss of control over these entities significantly impacted OpGen's operational structure and financial reporting.
• Financing and Capital Infusion [medium — financial]: In March 2024, OpGen secured $3.0 million in gross proceeds from the sale of Series E Convertible Preferred Stock to David E. Lazar. This stock was later acquired by AEI Capital Ltd. for $2.45 million in August 2024, and subsequently converted into 7,200,000 shares of common stock. This reliance on convertible preferred stock and subsequent capital transactions indicates potential ongoing financing needs and dilution risks.
• Strategic Pivot to Financial Services [medium — market]: OpGen has undergone a significant strategic pivot from precision medicine to financial services and technology. This transition involves establishing CapForce International Holdings Ltd. to offer capital market listing sponsorship and consultancy services, targeting companies with market capitalizations between $1 billion and $10 billion. The success of this new venture is unproven and subject to market adoption and competition.
• Development of Digital Investment Banking Platform [medium — operational]: CapForce is developing a global digital investment banking platform for cross-border securities trading, computational model-enabled advisory, and FinTech-enabled cap table management. The development and successful launch of such a complex platform carry significant execution risks and require substantial investment and expertise.
• Reverse Stock Splits [low — financial]: The company has implemented two reverse stock splits: a 1-for-20 split on January 5, 2023, and a 1-for-10 split on May 20, 2024. These actions are often taken to increase the per-share price of a stock, potentially to meet exchange listing requirements or improve investor perception, but can also signal underlying financial challenges.
• Small Market Capitalization [medium — market]: As of June 30, 2024, the aggregate market value of voting common stock held by non-affiliates was $3.3 million, indicating a small market capitalization. This can limit liquidity, investor interest, and the ability to raise further capital.

Industry Context

OpGen is transitioning from the precision medicine and molecular diagnostics sector to financial services and technology. The precision medicine market, while growing, is highly competitive and capital-intensive, with companies focusing on rapid diagnostics for infectious diseases. The financial services sector OpGen is entering is broad, with its new venture, CapForce, targeting capital market listing sponsorship and digital investment banking for mid-sized growth companies. This segment is characterized by established players and evolving FinTech solutions.

Regulatory Implications

The company's past operations in precision medicine were subject to healthcare and diagnostic regulations. Its current pivot to financial services exposes it to securities regulations, financial advisory rules, and potentially FinTech-specific compliance requirements. The successful navigation of these new regulatory landscapes will be critical for CapForce's operations and OpGen's overall compliance.

What Investors Should Do

1. Monitor CapForce's client acquisition and revenue generation.
2. Analyze the impact of AEI Capital Ltd.'s significant common stock holding.
3. Evaluate the execution risk of the digital investment banking platform.
4. Assess the long-term capital needs of the company.

Key Dates

• 2023-11-01: Insolvency filings for Curetis and Ares Genetics — Marked the beginning of the end for OpGen's precision medicine operations and necessitated a strategic shift.
• 2024-01-05: 1-for-20 reverse stock split — Adjusted share structure, likely to meet listing requirements or improve per-share price.
• 2024-03-01: Securities purchase agreement with David E. Lazar — Provided $3.0 million in gross proceeds, crucial for continued operations and strategic transition.
• 2024-04-01: Sale of Curetis and Ares Genetics assets — Formalized the exit from precision medicine and the deconsolidation of these subsidiaries.
• 2024-05-20: 1-for-10 reverse stock split — Further adjusted share structure following the strategic pivot and capital raise.
• 2024-08-01: AEI Capital Ltd. acquires Series E Preferred Stock and converts it — Resulted in AEI Capital Ltd. holding 7,200,000 shares of common stock, indicating a significant new stakeholder and potential influence.

Glossary

MDROs

Multidrug-resistant microorganisms, which are bacteria, viruses, fungi, or parasites that are resistant to one or more antimicrobial medicines. (OpGen's previous business focused on combating these infections through molecular diagnostics.)

Insolvency Proceedings

Legal processes initiated when a company is unable to pay its debts, often leading to the restructuring or liquidation of assets. (The insolvency of OpGen's subsidiaries Curetis and Ares Genetics was a pivotal event leading to the company's strategic pivot.)

Deconsolidation

The process of removing a subsidiary from a parent company's consolidated financial statements, typically due to loss of control. (OpGen deconsolidated Curetis and Ares Genetics due to their insolvency, significantly altering its financial reporting.)

Series E Convertible Preferred Stock

A class of preferred stock that can be converted into a predetermined number of common stock shares. (This type of stock was used by OpGen to raise capital, with a significant portion being converted into common stock by AEI Capital Ltd.)

Capital Market Listing Sponsorship

Services provided to companies seeking to list their shares on a stock exchange, including guidance on regulatory requirements and market introductions. (This is a core service of OpGen's new venture, CapForce International Holdings Ltd.)

Digital Investment Banking Platform

An online platform offering services traditionally provided by investment banks, such as securities trading, advisory, and capital table management, often leveraging technology. (This is a key development initiative for OpGen's CapForce subsidiary.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating them, increasing the per-share price. (OpGen has implemented two reverse stock splits, impacting its share structure and potentially its stock price.)

Year-Over-Year Comparison

The most significant change from the previous filing is OpGen's complete strategic pivot from precision medicine to financial services and technology. This follows the insolvency and deconsolidation of its key subsidiaries, Curetis and Ares Genetics. Consequently, revenue and financial metrics related to its former diagnostics business are no longer relevant. The company has also undergone significant capital restructuring, including reverse stock splits and the issuance and conversion of Series E Preferred Stock, indicating a focus on survival and a new business model rather than growth in its prior sector.

Key Financial Figures

• $2.58 — ed upon the last reported sale price of $2.58 per share on June 30, 2024), on The Nas
• $1.00 — rred Stock") to Mr. Lazar at a price of $1.00 per share for aggregate gross proceeds
• $3.0 million — r share for aggregate gross proceeds of $3.0 million. In connection with the transactions co
• $3.0 billion — pwide assets under management exceeding $3.0 billion. In conjunction with the transaction, M
• $2.45 million — ntly, AEI Capital Ltd. paid the Company $2.45 million in August 2024 in exchange for the rema
• $1 billion — th market capitalization values between $1 billion and $10 billion. OpGen, through CapForc
• $10 billion — alization values between $1 billion and $10 billion. OpGen, through CapForce, is also pursu
• $2.1 b — suers listed on U.S. exchanges, raising $2.1 billion, and as of March 31, 2025, 286 Ch
• $1.1 — United States collectively represented $1.1 trillion in market capitalization. Conc
• $135 billion — ervices is expected to be approximately $135 billion in 2025 and is projected to grow at a c
• $204 billion — of roughly 8.7% through 2030, reaching $204 billion by 2030. In parallel, foundational tool

Filing Documents

• opgeninc_10k.htm (10-K) — 1791KB
• opgeninc_ex21-1.htm (EX-21.1) — 2KB
• opgeninc_ex23-1.htm (EX-23.1) — 2KB
• opgeninc_ex31-1.htm (EX-31.1) — 11KB
• opgeninc_ex32-1.htm (EX-32.1) — 5KB
• 0001829126-25-006628.txt ( ) — 7807KB
• opgn-20241231.xsd (EX-101.SCH) — 67KB
• opgn-20241231_cal.xml (EX-101.CAL) — 63KB
• opgn-20241231_def.xml (EX-101.DEF) — 285KB
• opgn-20241231_lab.xml (EX-101.LAB) — 466KB
• opgn-20241231_pre.xml (EX-101.PRE) — 400KB
• opgeninc_10k_htm.xml (XML) — 1081KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 12 Item 1B. Unresolved Staff Comments 17 Item 1C. Cybersecurity 17 Item 2.

Properties

Properties 18 Item 3.

Legal Proceedings

Legal Proceedings 18 Item 4. Mine Safety Disclosures 18 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19 Item 6. [Reserved] 19 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 29 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 30 Item 9A.

Controls and Procedures

Controls and Procedures 30 Item 9B. Other Information 30 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 30 PART III Item 10. Directors, Executive Officers and Corporate Governance 31 Item 11.

Executive Compensation

Executive Compensation 37 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 41 Item 13. Certain Relationships and Related Person Transactions, and Director Independence 47 Item 14. Principal Accounting Fees and Services 48 PART IV Item 15. Exhibits and Financial Statement Schedules 49 Item 16. Form 10-K Summary 58

Signatures

Signatures 59 Consolidated Financial Statements F-1 i INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This annual report on Form 10-K for the year ended December 31, 2024 (the "Annual Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this Annual Report, we refer to OpGen, Inc. as the "Company", "OpGen", "we", "our" or "us". All statements, other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words "believe", "may", "will", "estimate", "continue", "anticipate", "design", "intend", "expect" or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A "Risk Factors". In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our liquidity and working capital requirements, including our cash requirements over the next 12 months; our ab

Business

Item 1. Business Please refer to the Glossary at the end of this Business section for definitions or descriptions of industry, regulatory, and OpGen-specific terms used in this Annual Report. Overview OpGen, Inc. ("OpGen" or the "Company") was incorporated in Delaware in 2001. In April 2020, OpGen completed its business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands. As part of the transaction, the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany ("Curetis"), and certain other assets and liabilities of Curetis GmbH, including all its shares of Ares Genetics GmbH ("Ares Genetics"). From inception through November 2023, the Company operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. In November 2023, the Company implemented certain cash management initiatives, including restructuring its U.S. operations by reducing headcount and scaling down operations at OpGen's U.S. headquarters to the core functions of a U.S. Nasdaq listed company, allowing the Company to conserve cash and focus on the functions needed to pursue potential strategic alternatives. In November 2023, Curetis filed a petition for insolvency with the district court of Stuttgart, Germany, and Ares Genetics filed a petition for insolvency with the commercial court in Vienna, Austria. The insolvency proceedings of Curetis and Ares Genetics were adjudicated under the insolvency laws of Germany and Aust

View Full Filing

View this 10-K filing on SEC EDGAR